ResMed Inc. ($RMD) Stock Forecast: Up 6.1% Today

What is ResMed Inc.?

ResMed Inc. (NYSE: RMD) is a prominent medical technology company known for its sleep apnea devices and masks. The company recently announced robust performance in the first quarter of fiscal 2025, showing a 34% increase in adjusted EPS and an 11% rise in sales, exceeding expectations.

Why is ResMed Inc. going up?

RMD stock is up 6.1% on Oct 25, 2024 16:42

• ResMed's strong Q1 financial results, fueled by growing demand for its sleep devices and masks, have driven a positive trend in its stock.
• The company's solid overall performance, evident in improved margins and surpassing financial projections, has instilled confidence among investors.
• Analysts consider ResMed a resilient player in the medical technology industry, underpinned by strong fundamentals, which likely attracted more investors and contributed to the upward movement in the market.

RMD Price Chart

RMD Technical Analysis

RMD News

Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst - ResMed ( NYSE:RMD )

On Thursday, ResMed Inc RMD reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04. The company reported sales of $1.224 billion, up 11%, beating the consensus of $1.18 billion, driven by increased demand for sleep devices and masks portfolio and ...

https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41548780/sleep-apnea-device-maker-resmed-is-a-durable-medtech-with-positive-fundamentals-say

ResMed's Stock Rises on Q1 Earnings and Revenue Beat, Margins Expand

RMD's stellar first-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.

https://www.zacks.com/stock/news/2357655/resmeds-stock-rises-on-q1-earnings-and-revenue-beat-margins-expand

ResMed ( RMD ) Surpasses Q1 Earnings and Revenue Estimates

ResMed (RMD) delivered earnings and revenue surprises of 8.37% and 2.98%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2357217/resmed-rmd-surpasses-q1-earnings-and-revenue-estimates

Unveiling ResMed ( RMD ) Q1 Outlook: Wall Street Estimates for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

https://www.zacks.com/stock/news/2353772/unveiling-resmed-rmd-q1-outlook-wall-street-estimates-for-key-metrics

Trending Today

Cardano ($ADA) Crypto Forecast: Up 22.7% Today

Dogecoin ($DOGE) Crypto Forecast: Up 9.1% Today

Kusama ($KSM) Crypto Forecast: Up 13.5% Today

Bonk ($BONK) Crypto Forecast: Down 6.2% Today

Pepe ($PEPE) Crypto Forecast: Down 5.1% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 7.7% Today

Uniswap ($UNI) Crypto Forecast: Up 9.3% Today

XRP ($XRP) Crypto Forecast: Up 16.2% Today

Filecoin ($FIL) Crypto Forecast: Up 9.4% Today

Aptos ($APT) Crypto Forecast: Up 5.1% Today

ResMed Inc. Price History

27.07.2024 - RMD Stock was up 5.0%

• ResMed's stock surged by 12% in the quarter, reflecting strong investor confidence in the company's growth prospects.
• Positive outlook from William Blair further boosted investor sentiment towards ResMed, indicating a favorable future trajectory for the stock.
• Despite an executive selling shares worth over $200k, the overall market sentiment remained positive, suggesting that investors were not significantly deterred by the insider selling.
• ResMed's consistent outperformance over the past decade, with an average annual return of 15.63%, has solidified its position as a strong investment choice, attracting more investors to the stock.

27.07.2024 - RMD Stock was up 5.8%

• The bullish movement in ResMed's stock today could be attributed to the positive long-term performance, where it outperformed the market by 4.82% annually over the past decade.
• The news of an executive selling shares worth over $200k might have initially raised concerns, but the overall market sentiment seems to have been unaffected, possibly due to the company's solid fundamentals and growth prospects.
• Investors may be optimistic about ResMed's future potential, considering its current market capitalization of $32.71 billion, indicating confidence in the company's ability to deliver sustained growth and value to shareholders.

25.09.2024 - RMD Stock was up 6.1%

• ResMed's strong Q1 financial results, fueled by growing demand for its sleep devices and masks, have driven a positive trend in its stock.
• The company's solid overall performance, evident in improved margins and surpassing financial projections, has instilled confidence among investors.
• Analysts consider ResMed a resilient player in the medical technology industry, underpinned by strong fundamentals, which likely attracted more investors and contributed to the upward movement in the market.

25.09.2024 - RMD Stock was up 5.9%

• ResMed (RMD) experienced a strong bullish movement today following the release of its Q1 earnings.
• The company surpassed both earnings and revenue estimates, indicating strong financial performance and market confidence.
• Investors likely responded positively to the results, showing optimism about ResMed's growth potential and ability to deliver consistent value to shareholders.
• The market movement could be attributed to the market's favorable reaction to ResMed's solid performance and optimistic outlook for future growth.

26.03.2024 - RMD Stock was up 7.6%

• The company's stock has seen a notable 12% surge over a period of three months due to increased demand for sleep devices.
• ResMed's quarterly results surpassed predictions, outperforming market expectations in terms of adjusted earnings and sales.
• Following the positive earnings report, analysts have raised their forecasts for ResMed.
• The company's impressive financial performance and the growing market demand for its products have been key factors driving the recent positive market movement.

29.03.2024 - RMD Stock was up 7.6%

• The bullish movement in ResMed Inc. (RMD) today can be attributed to several factors:
• Strong demand for sleep devices boosting investor confidence in the company's growth prospects.
• ResMed's recent quarterly report filing showing compliant and positive results, instilling trust in the market.
• The company's 12% surge over the past few months reflecting a consistent upward trend, attracting more investors.
• The stock hitting an 8-month high after a successful quarterly performance, overshadowing any previous concerns related to weight-loss drug issues, further reinforcing positive market sentiment towards ResMed.

24.05.2024 - RMD Stock was down 5.2%

• ResMed stock experienced a significant decline due to the negative impact of Eli Lilly's weight-loss drug on sleep apnea events, leading to investor concerns and selling pressure.
• A downgrade by Citi and reduction in stock target contributed to the bearish sentiment surrounding ResMed.
• The market was also influenced by Nvidia's third consecutive day of decline, leading to overall cautiousness among investors.
• Collaboration talks between ByteDance and Broadcom on an AI superprocessor may have diverted attention from traditional healthcare stocks like ResMed, impacting its performance negatively.

24.05.2024 - RMD Stock was down 5.0%

• ResMed shares fell sharply by 10.4% following the release of clinical trial results by another company showing the effectiveness of its weight-loss drug in reducing sleep apnea events.
• A financial analyst downgraded ResMed from Buy to Neutral, adding to the negative sentiment surrounding the stock.
• The news of a potential impact on ResMed's sales due to the efficacy of the weight-loss drug in treating sleep apnea likely contributed to the bearish movement in the stock.
• This event highlights the vulnerability of healthcare companies to developments in clinical trials and the competitive landscape, leading to significant market reactions.

21.05.2024 - RMD Stock was down 5.3%

• ResMed (RMD) stock moved downward despite the industry's positive growth trajectory.
• Factors like reduced demand for COVID-19-related products and financial restrictions in U.S. healthcare facilities could have influenced ResMed's revenue negatively.
• Supply chain limitations, higher material expenses, and workforce shortages in specific regions may have added to ResMed's challenges.
• While ResMed has historically outperformed the market, its stock price could have been impacted by the persistent obstacles and margin pressures outlined in the assessments.

26.06.2024 - RMD Stock was down 5.3%

• The downtrend in ResMed's stock today may be linked to concerns about the forthcoming earnings report, with expectations of limited earnings growth from Wall Street.
• While high-profile investors have been expressing optimism about ResMed, overall market sentiment appears cautious, leading to a potential stock sell-off.
• Variation in predictions between retail traders and Wall Street analysts regarding ResMed's earnings performance could be contributing to investor uncertainty, influencing today's bearish market activity.

26.06.2024 - RMD Stock was down 6.4%

• Despite historical market outperformance, ResMed (RMD) experienced a bearish movement today.
• High-rolling investors' bullish positioning in ResMed's options did not boost market sentiment.
• Uncertainty surrounding the upcoming earnings report may have led to the stock sell-off.
• Profit-taking by long-term investors with substantial gains in ResMed could have influenced today's bearish movement.

02.07.2024 - RMD Stock was up 5.3%

• Q4 earnings for ResMed exceeded estimates, with adjusted EPS up by 30% year over year, showcasing strong financial performance.
• Increased demand for sleep devices and masks led to revenue growth and improved margins, supported by cost efficiencies and a favorable product mix.
• CEO's confidence in addressing investor concerns about weight-loss drugs impacting sales further boosted investor sentiment, contributing to the stock's bullish movement.
• ResMed's robust financials, positive market dynamics, and management's strategic reassurances likely fueled the day's bullish momentum in the stock.